Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Singulair

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Singulair was produced by Merck & Co..

India denies patent on Pfizer's Xeljanz

India denies patent on Pfizer's Xeljanz

Earlier cases have involved Novartis' cancer drug Glivec (imatinib), Roche 's Pegasys (peginterferon alfa-2a) for hepatitis, Merck &Co's asthma treatment Singulair (montelukast), Gilead's HIV drug Viread (tenofovir) and

Merck & Co's cancer drug Keytruda gaining traction in US

Merck & Co's cancer drug Keytruda gaining traction in US Merck's third-quarter results were hit as expected by the lingering effect of patent expiries on key products such as cancer drug Temodar (temozolomide) and Singulair (montelukast) for asthma, as

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte sales of asthma drug Singulair (montelukast) on generic competition, as well as a 14 per cent drop in net income to $781m.

Who tops the pharma list?

Who tops the pharma list? By the end of 2012, Advair (GSK - $8.2bn), Singulair (Merck - $5.5bn) and Diovan (Novartis - $5.7bn) would be among many billion-dollar brands to lose exclusivity during the calendar

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics